title: High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group.
abstract: Forty-four of 50 adult patients with advanced soft-tissue sarcoma who had received previous chemotherapy were evaluable for response after treatment with DTIC. The therapeutic schedule consisted of DTIC 1.2 g/m2 infused over 20 minutes, and repeated every 3 weeks. There were 1 complete and 7 partial remissions (objective activity 18%, 95% C.I. 7%-29%), with a median duration of 8 weeks (range 5-19), with the complete remission lasting 1 yr. Hematologic toxicity was dose-limiting; W.H.O. greater than or equal to 3 values were observed for WBC in 36%, and for platelets in 26% of patients. The non-hematologic toxicity included nausea and vomiting (90%), a flu-like syndrome (49%), diarrhea (35%), pain in the infused vein (28%) and hypotensive episodes (4%). Intermittent high-dose DTIC is active in advanced soft-tissue sarcoma and should be considered for inclusion in combination regimens.
authors.affiliation: Hospital General de Asturias, Oviedo, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Buesa
authors.forename: H T
authors.initials: HT
authors.lastname: Mouridsen
authors.forename: A T
authors.initials: AT
authors.lastname: van Oosterom
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: T
authors.initials: T
authors.lastname: Wagener
authors.forename: W
authors.initials: W
authors.lastname: Steward
authors.forename: A
authors.initials: A
authors.lastname: Poveda
authors.forename: P M
authors.initials: PM
authors.lastname: Vestlev
authors.forename: D
authors.initials: D
authors.lastname: Thomas
authors.forename: R
authors.initials: R
authors.lastname: Sylvester
mesh_terms: D000328:Adult; D000368:Aged; D003606:Dacarbazine / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*
chemical_list: D003606:Dacarbazine